Search Results - "Palma, Benedetta Dalla"

Refine Results
  1. 1

    Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling by Aversa, Franco, Dalla Palma, Benedetta, Bolzoni, Marina, Toscani, Denise, Accardi, Fabrizio, Giuliani, Nicola

    Published in BioMed research international (01-01-2015)
    “…Multiple myeloma (MM) is characterized by a high capacity to induce alterations in the bone remodeling process. The increase in osteoclastogenesis and the…”
    Get full text
    Journal Article
  2. 2

    Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma by Dalla Palma, Benedetta, Marchica, Valentina, Catarozzo, Maria Teresa, Giuliani, Nicola, Accardi, Fabrizio

    Published in Journal of clinical medicine (19-09-2020)
    “…B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily, is universally expressed by normal and neoplastic plasma cells…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies by Storti, Paola, Costa, Federica, Marchica, Valentina, Burroughs-Garcia, Jessica, dalla Palma, Benedetta, Toscani, Denise, Eufemiese, Rosa Alba, Giuliani, Nicola

    Published in Journal of clinical medicine (04-09-2020)
    “…The monoclonal antibodies (mAbs) have significantly changed the treatment of multiple myeloma (MM) patients. However, despite their introduction, MM remains an…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8

    Identification of clinical‐biological features of newly diagnosed early relapse multiple myeloma patients eligible for autologous stem cell transplantation by Cillo, Lorenzo, Palma, Anna Benedetta Dalla, Ricci, Stefania, Pedrazzoni, Mario, Scita, Matteo, Bernardi, Matia, Sammarelli, Gabriella, Pelagatti, Laura, Giuliani, Nicola

    Published in EJHaem (01-08-2024)
    “…A portion of multiple myeloma (MM) patients relapse early or do not respond to first line treatment. Identification of possible clinical and or biological…”
    Get full text
    Journal Article
  9. 9

    CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents by Costa, Federica, Dalla Palma, Benedetta, Giuliani, Nicola

    Published in Cells (Basel, Switzerland) (13-12-2019)
    “…In the last decades CD38 has emerged as an attractive target for multiple myeloma (MM). CD38 is a novel multifunctional glycoprotein that acts as a receptor,…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13

    CD14+CD16+ monocytes are involved in daratumumab‐mediated myeloma cells killing and in anti‐CD47 therapeutic strategy by Storti, Paola, Vescovini, Rosanna, Costa, Federica, Marchica, Valentina, Toscani, Denise, Dalla Palma, Benedetta, Craviotto, Luisa, Malavasi, Fabio, Giuliani, Nicola

    Published in British journal of haematology (01-08-2020)
    “…Summary A deep elucidation of the mechanisms of action of anti‐CD38 monoclonal antibodies (mAbs), such as daratumumab (DARA), is required to identify patients…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results by Fazzi, Rita, Petrini, Iacopo, Giuliani, Nicola, Morganti, Riccardo, Carulli, Giovanni, Dalla Palma, Benedetta, Notarfranchi, Laura, Galimberti, Sara, Buda, Gabriele

    Published in Frontiers in immunology (03-02-2021)
    “…Maintenance treatment after autologous bone marrow transplantation in multiple myeloma improves the outcome of patients. We designed a phase II clinical trial…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20